신경내분비종양 치료 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 제품별, 부위별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Type (Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma), By Product, By Site, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,530,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,964,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,831,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

신경내분비종양 치료 시장의 성장과 동향

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 신경내분비종양 치료 시장 규모는 2030년까지 37억 3,000만 달러에 달할 전망입니다.

이 시장은 2025-2030년에 CAGR 6.0%를 기록할 것으로 추정되고 있습니다. 카르티노이드 종양의 확산이 증가하면서 예측 기간 중 시장을 촉진할 것으로 예상됩니다. 다양한 제약사들이 신제품을 개발하기 위해 임상시험에 많은 투자를 하고 있는 것도 시장 개척을 촉진하는 요인 중 하나입니다.

예를 들어 Novartis AG의 임상 검사 수가 가장 많고, Pfizer Inc.와 Ipsen Pharma가 그 뒤를 잇고 있습니다. 또한 신경내분비종양 치료를 위한 치료법의 기술적 발전은 향후 수년간 시장 성장을 가속할 것으로 예상됩니다. 여기에는 Ga 표지 소마토스타틴을 이용한 PET 영상, 표적 약물 요법, 티로신 키나아제 요법 등이 포함됩니다. 예를 들어 Novartis AG의 Lutathera는 역사상 최초의 방사성 뉴클레오티드 치료제로 FDA의 승인을 받았습니다.

신경내분비 종양 치료 시장 보고서 하이라이트

• 카르티노이드 종양 유병률 증가와 치료법 발전으로 인해 2024년 카르티노이드 종양 부문이 24.3%의 매출 점유율을 차지하며 시장을 주도했습니다.
• 소마토스타틴 유사체(SSAs) 부문은 신경내분비종양과 관련된 증상 관리에 효과적임이 입증되며, 2024년 매출 점유율 1위를 차지했습니다.
• 소장 부문은 2024년 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
• 병원 부문은 병원이 신경내분비종양의 복잡한 사례에 대한 종합적인 치료를 제공함에 따라 2024년 가장 큰 매출 점유율을 차지하며 시장을 독점했습니다.
• 북미 신경내분비종양 치료 시장은 2024년 42.1%의 매출 점유율로 세계 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 신경내분비종양 치료 시장의 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 신경내분비종양 치료 시장 : 유형별 비즈니스 분석

• 유형 시장 점유율, 2024년과 2030년
• 유형 부문 대시보드
• 시장 규모와 예측과 동향 분석, 유형별, 2018-2030년
• 수막종
• 부신암
• 카르시노이드 종양
• 부신경절종
• 갈색세포종
• 기타

제5장 신경내분비종양 치료 시장 : 제품 비즈니스 분석

• 제품 시장 점유율, 2024년과 2030년
• 제품 부문 대시보드
• 시장 규모와 예측과 동향 분석, 제품별, 2018-2030년
• 소마토스타틴 유사체(SSA)
• 표적치료
• 기타

제6장 신경내분비종양 치료 시장 : 부위 비즈니스 분석

• 부위 시장 점유율, 2024년과 2030년
• 부위 부문 대시보드
• 시장 규모와 예측과 동향 분석, 부위별, 2018-2030년
• 폐
• 췌장
• 결장
• 소장
• 직장
• 위
• 기타

제7장 신경내분비종양 치료 시장 : 최종 용도 비즈니스 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 최종 용도 부문 대시보드
• 시장 규모와 예측과 동향 분석, 최종 용도별, 2018-2030년
• 병원
• 클리닉
• 기타

제8장 신경내분비종양 치료 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 싱가포르
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 참가자 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요/상장기업
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Hutchison MediPharma Limited.
  • AVEO Pharmaceuticals, Inc.
  • Ipsen Pharma.
  • Eli Lilly and Company.
  • Exelixis, Inc.
  • Jubilant Pharmova Limited

KSA

영문 목차

영문목차

Neuroendocrine Tumor Treatment Market Growth & Trends:

The global neuroendocrine tumor treatment market size is expected to reach USD 3.73 billion by 2030, according to a new report by Grand View Research, Inc. The market is estimated to register a CAGR of 6.0% from 2025 to 2030. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

Neuroendocrine Tumor Treatment Market Report Highlights:

• The carcinoid tumors segment dominated the market with a revenue share of 24.3% in 2024, driven by the increasing prevalence of carcinoid tumors and advancements in treatment methodologies.
• The Somatostatin Analogs (SSAs) segment dominated the market with the largest revenue share in 2024, attributed to their proven efficacy in managing symptoms associated with neuroendocrine tumors.
• The small intestine segment dominated the market with the largest revenue share in 2024, attributed to the higher incidence rates of neuroendocrine tumors originating from this site.
• The hospitals segment dominated the market with the largest revenue share in 2024, driven by the comprehensive care offered by hospitals for complex cases of neuroendocrine tumors.
• North America neuroendocrine tumor treatment market dominated the global market with a revenue share of 42.1% in 2024, driven by high healthcare expenditure coupled with advanced medical infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. Site
  • 1.2.4. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Neuroendocrine Tumor Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Neuroendocrine Tumor Treatment Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
• 4.4. Meningiomas
  • 4.4.1. Meningiomas Market, 2018 - 2030 (USD Billion)
• 4.5. Adrenal Cancer
  • 4.5.1. Adrenal Cancer Market, 2018 - 2030 (USD Billion)
• 4.6. Carcinoid Tumors
  • 4.6.1. Carcinoid Tumors Market, 2018 - 2030 (USD Billion)
• 4.7. Paraganglioma
  • 4.7.1. Paraganglioma Market, 2018 - 2030 (USD Billion)
• 4.8. Pheochromocytoma
  • 4.8.1. Pheochromocytoma Market, 2018 - 2030 (USD Billion)
• 4.9. Others
  • 4.9.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 5. Neuroendocrine Tumor Treatment Market: Product Business Analysis

• 5.1. Product Market Share, 2024 & 2030
• 5.2. Product Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
• 5.4. Somatostatin Analogs (SSAs)
  • 5.4.1. Somatostatin Analogs (SSAs)Market, 2018 - 2030 (USD Billion)
• 5.5. Targeted Therapy
  • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Neuroendocrine Tumor Treatment Market: Site Business Analysis

• 6.1. Site Market Share, 2024 & 2030
• 6.2. Site Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Site, 2018 to 2030 (USD Billion)
• 6.4. Lung
  • 6.4.1. Lung Market, 2018 - 2030 (USD Billion)
• 6.5. Pancreas
  • 6.5.1. Pancreas Market, 2018 - 2030 (USD Billion)
• 6.6. Colon
  • 6.6.1. Colon Market, 2018 - 2030 (USD Billion)
• 6.7. Small Intestine
  • 6.7.1. Small Intestine Market, 2018 - 2030 (USD Billion)
• 6.8. Rectum
  • 6.8.1. Rectum Market, 2018 - 2030 (USD Billion)
• 6.9. Stomach
  • 6.9.1. Stomach Market, 2018 - 2030 (USD Billion)
• 6.10. Others
  • 6.10.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Neuroendocrine Tumor Treatment Market: End Use Business Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. End Use Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
• 7.4. Hospitals
  • 7.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 7.5. Clinics
  • 7.5.1. Clinics Market, 2018 - 2030 (USD Billion)
• 7.6. Others
  • 7.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Neuroendocrine Tumor Treatment Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.5. Europe
  • 8.5.1. Europe Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6.7. Singapore
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Singapore Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Latin America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 8.8. MEA
  • 8.8.1. MEA Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novartis AG
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Type Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Bristol-Myers Squibb Company
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Type Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Pfizer Inc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Type Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Boehringer Ingelheim International GmbH
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Type Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Hutchison MediPharma Limited.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Type Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AVEO Pharmaceuticals, Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Type Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Ipsen Pharma.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Type Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Eli Lilly and Company.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Type Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Exelixis, Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Type Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Jubilant Pharmova Limited
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Type Benchmarking
    • 9.5.10.4. Strategic Initiatives

관련자료